Company

Bicycle Therapeutics plc

Headquarters: Cambridge, United Kingdom

Employees: 119

CEO: Dr. Kevin Lee M.B.A., Ph.D.

NASDAQ: BCYC -3.17%

Market Cap

$1.39 Billion

USD as of July 1, 2024

Market Cap History

Bicycle Therapeutics plc market capitalization over time

Evolution of Bicycle Therapeutics plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Bicycle Therapeutics plc

Detailed Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Top 1-year algo backtest: +207.50%

$10,000 in July 2023 would now be $30,750 by following this algorithm daily at market close.

Boost your returns with Disfold DeepFinance... Now!

Try Disfold DeepFinance FREE

Stocks & Indices

Bicycle Therapeutics plc has the following listings and related stock indices.


Stock: NASDAQ: BCYC wb_incandescent

Details

Headquarters:

Babraham Research Campus

Building 900

Cambridge, CB22 3AT

United Kingdom

Phone: 44 1223 261 503